Heliospect Genomics' website now redirects embryo-screening inquiries to Herasight, whose team page lists the same CEO and bioethicist named in the 2024 investigation

heliospect-genomicsherasightpolygenic-embryo-selectionjonathan-anomalycorroboration

Heliospect Genomics' own website, read directly on 2026-09-07, is a sparse page that no longer mentions embryos or IQ; it tells visitors: "Interested in embryo screening? Please visit: herasight.com." Herasight's own team page, read the same day, lists fourteen names including "Jonathan Anomaly" and "Michael Christensen" — the exact two people the 2024 Guardian/Hope Not Hate investigation identified as Heliospect's CEO (Christensen) and in-house bioethicist advisor (Anomaly). See entity-jonathan-anomaly.

This is a direct, Tier 1 primary-source link — both companies' own websites, no secondary reporting involved — between the entity investigated in 2024 and the entity now operating publicly under a new name. Heliospect's page also describes its ongoing work in terms that independently corroborate the general technical mechanism (though not the embryo/IQ application specifically) the 2024 investigation described: "Our focus is on utilizing polygenic scores and genome-wide association studies (GWAS) to improve our understanding of the genetic basis of disease and human behavior. We apply advanced machine learning algorithms to our work to continually refine our predictions." This note answers part (a) of question-corroborate-heliospect-genomics-iq-embryo-investigation — Heliospect's own materials — though it corroborates personnel continuity and general mechanism, not the specific 2024 figures (couples served, price, IQ-point claim), which remain tracked separately in claim-heliospect-2024-quant-figures-remain-uncorroborated-by-independent-reporting.